Related Experiment Video
Updated: Jul 5, 2026

Aortic Ring Assay
Published on: November 24, 2009
Erythropoietin has an antiapoptotic effect after myocardial infarction and stimulates in vitro aortic ring sprouting
Agneta Månsson Broberg1, Karl-Henrik Grinnemo, Rami Genead
1Department of Cardiology, M52 Karolinska University Hospital, S14186 Stockholm, Sweden.
Abstract:
Aims were to explore if darbepoietin-alpha in mouse can induce angiogenesis and if moderate doses after myocardial infarction stimulates periinfarct capillary and arteriolar densities, cell proliferation, and apoptosis. Myocardial infarction was induced by ligation of LAD. Mouse aortic rings (0.8mm) were cultured in matrigel and the angiogenic sprouting was studied after addition of darbepoietin-alpha with and without VEGF-165. After 12 days the hemoglobin concentration was 25% higher in the darbepoietin-alpha treated mice than in the control group. No difference in capillary densities in the periinfarct or noninfarcted areas was seen with darbepoietin-alpha. Cell proliferation was about 10 times higher in the periinfarct area than in the noninfarcted wall. Darbepoietin-alpha treatment led to a decrease of cell proliferation (BrdU, (p<0.02)) and apoptosis (TUNEL, p<0.005) with about 30% in the periinfarct area. Darbepoietin-alpha and VEGF-165 both independently induced sprouting from aortic rings. The results suggest that darbepoietin-alpha can induce angiogenesis but that moderate doses after myocardial infarction are not angiogenic but antiapoptotic.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Factors Affecting Erythropoiesis
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Erythropoiesis
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Inotropic Agents

